add directory ♦ travel nurse jobs
Today's News:
Pharma Industry / Biotech Industry News From Medical News Today
BSI British Standards Publishes New Glossary To Help Promote The Safe And Efficient Commercialisation Of Regenerative Medicine Products In The UK
Fri, 16 May 2008 00:00:00 -0700
BSI British Standards has published a Publicly Available Specification (PAS) which defines the terms commonly used in the field of regenerative medicine. PAS 84, Regenerative Medicine - Glossary, provides clear guidance on the meaning of terminology currently used in the UK by industry, regulators, government and academia.
10 VPs 85% Pharma Meet At Eyeforpharma's SFE USA 2008 Summit
Fri, 16 May 2008 00:00:00 -0700
There are currently 10 Pharma VPs and over 85% pharma meeting at eyeforpharma's Sales Force Effectiveness USA Summit. eyeforpharma have announced that the summit will sell out. The two day event taking place June 23-24 in Philadelphia, USA, comprises presentation sessions, roundtables, workshops, a networking evening and an exhibition.
Speakers Announced For The Pharma Marketing Summit 2008 In Zurich
Fri, 16 May 2008 00:00:00 -0700
Eyeforpharma has announced 9 of their 30 speakers for Europe's biggest and most influential marketing strategy conference for pharma on 20-21st October in Zurich. The conference, now in its 8th year, is yet to be officially launched.
Senators Praise Growing Support For Transparency In Drug Industry Payments To Physicians, USA
Thu, 15 May 2008 04:00:00 -0700
The newly announced backing of a leading drug maker for a national registry of industry payments to medical doctors indicates that transparency's time has come, according to Senators Chuck Grassley and Herb Kohl, co-authors of pending legislation to establish such a registry.
ISPE-PCC Awards Credential To Industry Professional
Thu, 15 May 2008 03:00:00 -0700
Michael D. Ruff, R. Ph., CPIP, Vice President of Pharmaceutical Development for Metrics, Inc., has met the global competency standard and has been conferred the Certified Pharmaceutical Industry Professional (CPIP SM) credential by the ISPE Professional Certification Commission (ISPE-PCC). Ruff is one of nine professionals to be awarded this new certification and was assessed through demonstrated education, industry experience, and a rigorous examination.
Medicines Australia Surprised By PBAC Measure
Thu, 15 May 2008 01:00:00 -0700
Medicines Australia chief executive Ian Chalmers said tonight he was surprised and disappointed by the Government's controversial Budget measure forcing the pharmaceutical industry to fund the Government's own Pharmaceutical Benefits Advisory Committee. While welcoming several health funding announcements in the Budget, Mr Chalmers said the Government's move to recover the cost of the PBAC was inappropriate.
Annals of Pharmacotherapy PAP Articles
Inadvertent Administration of Intravenous Ziprasidone Leading to Bradycardia and QT Interval Prolongation (June)
Bentley, M. L, Biscardi, F. H, Butcher, C. Tue, 13 May 2008 00:00:00 -0000
Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin (June) (CE)
Anderson, S. D, Gums, J. G Tue, 13 May 2008 00:00:00 -0000
OBJECTIVE: To summarize and evaluate the literature concerning ceftobiprole. DATA SOURCES: Literature identification was conducted through MEDLINE (1966-February 2008) and International Pharmaceutical Abstracts (1970-February 2008) using the terms ceftobiprole, medocaril, BAL 5788, R0-5788, BAL 9141, RO 63-9141, pyrrolidinone cephalosporin, MRSA, complicated skin and skin-structure infections (cSSSIs), community-acquired pneumonia, and nosocomial pneumonia. Additional publications were identified through a review of articles and abstracts from infectious disease meetings. STUDY SELECTION AND DATA EXTRACTION: All articles in English were evaluated and all pertinent information was included. DATA SYNTHESIS: Ceftobiprole medocaril is an extended-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus spp., vancomycin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa. Inactivity includes extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and Enterococcus faecium. Preliminary data suggest that ceftobiprole may be effective with a 1-hour infusion of 500 mg every 12 hours for gram-positive infections and 500 mg every 8 hours with a 2-hour infusion for polymicrobial infections. Two clinical trials support these dosing regimens for cSSSIs. Ceftobiprole was noninferior to vancomycin in suspected gram-positive cSSSIs, with cure rates of 93.3% and 93.5%, respectively. Furthermore, ceftobiprole was noninferior to vancomycin and ceftazidime in polymicrobial cSSSIs (cure rates 90.5% vs 90.2%, respectively). Although the total number of adverse effects was similar to those of the comparator, more patients in the ceftobiprole group experienced nausea, vomiting, and dysgeusia. CONCLUSIONS: The activity of ceftobiprole and limited clinical data suggest that it may be useful as empiric monotherapy for cSSSI and in combination with other antimicrobials in lower respiratory tract infections for which Phase 3 clinical trials are currently exploring. Although not shown in vitro, ceftobiprole may induce resistance due to its broad spectrum of activity. Approval is expected for the treatment of cSSSI.
Practice Change in Community Pharmacy: Quantification of Facilitators (June)
Roberts, A. S, Benrimoj, S. I, Chen, T. F, Williams, K. A, Aslani, P. Tue, 13 May 2008 00:00:00 -0000
BACKGROUND: There has been an increasing international trend toward the delivery of cognitive pharmaceutical services (CPS) in community pharmacy. CPS have been developed and disseminated individually, without a framework underpinning their implementation and with limited knowledge of factors that might assist practice change. The implementation process is complex, involving a range of internal and external factors. OBJECTIVE: To quantify facilitators of practice change in Australian community pharmacies. METHODS: We employed a literature review and qualitative study to facilitate the design of a 43-item "facilitators of practice change" scale as part of a quantitative survey instrument, using a framework of organizational theory. The questionnaire was pilot-tested (n = 100), then mailed to a random sample of 2000 community pharmacies, with a copy each for the pharmacy owner, employed pharmacist, and pharmacy assistant. The construct validity and reliability of the scale were established using exploratory factor analysis and Cronbach's , respectively. RESULTS: A total of 735 (37%) pharmacies responded, with 1303 individual questionnaires. Factor analysis of the scale yielded 7 factors, explaining 48.8% of the total variance. The factors were: relationship with physicians (item loading range 0.59-0.85; Cronbach's a 0.90), remuneration (0.52-0.74; 0.82), pharmacy layout (0.52-0.79; 0.81), patient expectation (0.52-0.85; 0.82), manpower/staff (0.49-0.66; 0.80), communication and teamwork (0.37-0.65; 0.77), and external support/assistance (0.47-0.69; 0.74). CONCLUSIONS: All of the factors demonstrated good reliability and construct validity and explained approximately half of the variance. Implementing CPS requires support not only with the clinical aspects of service delivery, but also for the process of implementation itself, and remuneration models must reflect this. The identified facilitators should be used in a multilevel strategy to integrate professional services into the community pharmacy business, engaging pharmacists and their staff, policy makers, educators, and researchers. Further research is required to determine additional factors impacting the capacity of community pharmacies to implement change.
Correction: Intravenous Human Plasma-Derived Augmentation Therapy in {alpha}1-Antitrypsin Deficiency: From Pharmacokinetic Analysis to Individualizing Therapy (June)
Tue, 13 May 2008 00:00:00 -0000
Formulary Management of Recombinant Factor VIIa at an Academic Medical Center (June)
Owen, P. S, Golightly, L. K, MacLaren, R., Ferretti, K. A, Badesch, D. B Tue, 13 May 2008 00:00:00 -0000
BACKGROUND: Recombinant human coagulation factor VIIa (rVIIa) is a procoagulant indicated for treatment of bleeding in patients with hemophilia. A large proportion of rVIIa utilization is for off-label administration in nonhemophiliac patients with acute hemorrhage. Concerns of potentially inappropriate use, safety, and cost of rVIIa led to efforts to standardize use of this agent. OBJECTIVE: To comparatively describe the utilization of rVIIa upon implementation of an evidence-based guideline at a university hospital. METHODS: With advisory direction from a multidisciplinary task force, an evidence-based guideline for use of rVIIa was developed, approved, and fully implemented. Assessment of appropriateness of use and retrospective review were required for all cases. Effects of these actions were evaluated by auditing and comparing rVIIa use in patients treated in two 6-month observation periods before and after guideline implementation. Outcomes assessed were proportions of patients deemed appropriate to receive rVIIa, compliance with dosing recommendations, and acquisition costs. RESULTS: Twenty-two and 29 patients were treated in the periods before and after guideline implementation, respectively. Patient characteristics were similar, except more cardiothoracic surgeries were performed in patients treated before implementation of the guideline. Indications for rVIIa use were judged appropriate in 21 (95.5%) before-cases and in all (100%) after-cases. The dose was compliant in 1 (4.6%) before-case and 27 (93.1%) after-cases (p < 0.001). Mean dosages of rVIIa administered were 81.8 µg/kg and 45.3 µg/kg in before- and after-cases, respectively (p < 0.001). During the respective periods of observation, amounts of rVIIa purchased monthly averaged 42.6 mg and 21.8 mg, a 49% difference. Semiannual expenditures for rVIIa decreased approximately $110,000 following guideline implementation. Patient outcomes were similar. CONCLUSIONS: A guideline based on currently available evidence can serve to sustain the clinical appropriateness of rVIIa therapy and substantially decrease costs.
Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand (June)
Wheeler, A. J Tue, 13 May 2008 00:00:00 -0000
OBJECTIVE: To describe the treatment pathway and patterns of clozapine use in patients with schizophrenia, including coprescribed psychotropic medications, and compare the extent of coprescribing of clozapine with that of non-clozapine schizophrenia treatment in community mental health services in the Auckland and Northland regions of New Zealand. METHODS: A retrospective chart review was conducted for adult outpatients receiving care from community mental health services on October 31, 2004. Data collected for all patients prescribed an antipsychotic included demographics (sex, age, ethnicity); principal diagnosis (Diagnostic and Statistical Manual of Mental Disorders, 4th edition); comorbid conditions; duration of mental illness; psychiatric admissions; and treatment information (psychotropic medications, with dose and route of administration). If clozapine had been started after the introduction of full government prescription subsidy (February 1999), additional data, including year of initiation and prior antipsychotic history, were collected. Analysis included all outpatients with a diagnosis of schizophrenia (including schizoaffective disorder). RESULTS: Antipsychotics were prescribed for 2796 schizophrenia patients; 32.8% were prescribed clozapine, with a mean dose of 372 mg/day and an average duration of illness of 9.7 years before starting clozapine. Patients who had started treatment after clozapine was funded by the government (59.3%) had received a median of 3 antipsychotic drugs prior to starting clozapine; most of the treatment regimens included 1 second-generation antipsychotic (91.2%). Clozapine patients were less likely to be coprescribed another antipsychotic compared with non-clozapine patients (11.7% vs 17.6%; p < 0.001). Both the clozapine and nonclozapine groups had a low total number of psychotropic medications prescribed (median 2); for clozapine patients, the second drug was most likely to be for treatment of hypersalivation. CONCLUSIONS: Outpatients with treatment-resistant schizophrenia were prescribed clozapine at expected rates; however, treatment was delayed longer than recommended. There is some evidence that access to clozapine for treatment-resistant schizophrenia has improved, possibly as the result of the introduction of government subsidy, guideline dissemination, or increasing experience of clinicians with use of clozapine. In this real-world environment, the number of concomitant psychotropic medications for outpatients with schizophrenia was found to be low; when used concomitantly used with clozapine, they were most commonly used to manage adverse effects.
Clinical Pharmacology & Therapeutics
In This Issue
In This Issue Clinical Pharmacology & Therapeutics 83, 373 (March 2008). doi:10.1038/sj.clpt.6100521
Pharmacoecology: A New Name for an Old Science
C Flexner Pharmacoecology: A New Name for an Old Science Clinical Pharmacology & Therapeutics 83, 375 (March 2008). doi:10.1038/sj.clpt.6100499 Author: C Flexner
News and Views
News and Views Clinical Pharmacology & Therapeutics 83, 380 (March 2008). doi:10.1038/sj.clpt.6100522 Author:
News and Views
News and Views Clinical Pharmacology & Therapeutics 83, 382 (March 2008). doi:10.1038/sj.clpt.6100520
Principles of Clinical Pharmacology, 2nd Edition
SG Carruthers Principles of Clinical Pharmacology, 2nd Edition Clinical Pharmacology & Therapeutics 83, 384 (March 2008). doi:10.1038/sj.clpt.6100485 Author: SG Carruthers
Special Cells, Special Considerations: The Challenges of Bringing Embryonic Stem Cells From the Laboratory to the Clinic
RC AddisJWM BulteJD Gearhart Special Cells, Special Considerations: The Challenges of Bringing Embryonic Stem Cells From the Laboratory to the Clinic Clinical Pharmacology & Therapeutics 83, 386 (March 2008). doi:10.1038/sj.clpt.6100384 Authors: RC Addis, JWM Bulte & JD Gearhart
Subscribe to Pharmacology RSS feed 
BSI British Standards Publishes New Glossary To Help Promote The Safe And Efficient Commercialisation Of Regenerative Medicine Products In The UK
Fri, 16 May 2008 00:00:00 -0700
BSI British Standards has published a Publicly Available Specification (PAS) which defines the terms commonly used in the field of regenerative medicine. PAS 84, Regenerative Medicine - Glossary, provides clear guidance on the meaning of terminology currently used in the UK by industry, regulators, government and academia.
10 VPs 85% Pharma Meet At Eyeforpharma's SFE USA 2008 Summit
Fri, 16 May 2008 00:00:00 -0700
There are currently 10 Pharma VPs and over 85% pharma meeting at eyeforpharma's Sales Force Effectiveness USA Summit. eyeforpharma have announced that the summit will sell out. The two day event taking place June 23-24 in Philadelphia, USA, comprises presentation sessions, roundtables, workshops, a networking evening and an exhibition.
Speakers Announced For The Pharma Marketing Summit 2008 In Zurich
Fri, 16 May 2008 00:00:00 -0700
Eyeforpharma has announced 9 of their 30 speakers for Europe's biggest and most influential marketing strategy conference for pharma on 20-21st October in Zurich. The conference, now in its 8th year, is yet to be officially launched.
Senators Praise Growing Support For Transparency In Drug Industry Payments To Physicians, USA
Thu, 15 May 2008 04:00:00 -0700
The newly announced backing of a leading drug maker for a national registry of industry payments to medical doctors indicates that transparency's time has come, according to Senators Chuck Grassley and Herb Kohl, co-authors of pending legislation to establish such a registry.
ISPE-PCC Awards Credential To Industry Professional
Thu, 15 May 2008 03:00:00 -0700
Michael D. Ruff, R. Ph., CPIP, Vice President of Pharmaceutical Development for Metrics, Inc., has met the global competency standard and has been conferred the Certified Pharmaceutical Industry Professional (CPIP SM) credential by the ISPE Professional Certification Commission (ISPE-PCC). Ruff is one of nine professionals to be awarded this new certification and was assessed through demonstrated education, industry experience, and a rigorous examination.
Medicines Australia Surprised By PBAC Measure
Thu, 15 May 2008 01:00:00 -0700
Medicines Australia chief executive Ian Chalmers said tonight he was surprised and disappointed by the Government's controversial Budget measure forcing the pharmaceutical industry to fund the Government's own Pharmaceutical Benefits Advisory Committee. While welcoming several health funding announcements in the Budget, Mr Chalmers said the Government's move to recover the cost of the PBAC was inappropriate.
Annals of Pharmacotherapy PAP Articles
Inadvertent Administration of Intravenous Ziprasidone Leading to Bradycardia and QT Interval Prolongation (June)
Bentley, M. L, Biscardi, F. H, Butcher, C. Tue, 13 May 2008 00:00:00 -0000
Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin (June) (CE)
Anderson, S. D, Gums, J. G Tue, 13 May 2008 00:00:00 -0000
OBJECTIVE: To summarize and evaluate the literature concerning ceftobiprole. DATA SOURCES: Literature identification was conducted through MEDLINE (1966-February 2008) and International Pharmaceutical Abstracts (1970-February 2008) using the terms ceftobiprole, medocaril, BAL 5788, R0-5788, BAL 9141, RO 63-9141, pyrrolidinone cephalosporin, MRSA, complicated skin and skin-structure infections (cSSSIs), community-acquired pneumonia, and nosocomial pneumonia. Additional publications were identified through a review of articles and abstracts from infectious disease meetings. STUDY SELECTION AND DATA EXTRACTION: All articles in English were evaluated and all pertinent information was included. DATA SYNTHESIS: Ceftobiprole medocaril is an extended-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus spp., vancomycin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa. Inactivity includes extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and Enterococcus faecium. Preliminary data suggest that ceftobiprole may be effective with a 1-hour infusion of 500 mg every 12 hours for gram-positive infections and 500 mg every 8 hours with a 2-hour infusion for polymicrobial infections. Two clinical trials support these dosing regimens for cSSSIs. Ceftobiprole was noninferior to vancomycin in suspected gram-positive cSSSIs, with cure rates of 93.3% and 93.5%, respectively. Furthermore, ceftobiprole was noninferior to vancomycin and ceftazidime in polymicrobial cSSSIs (cure rates 90.5% vs 90.2%, respectively). Although the total number of adverse effects was similar to those of the comparator, more patients in the ceftobiprole group experienced nausea, vomiting, and dysgeusia. CONCLUSIONS: The activity of ceftobiprole and limited clinical data suggest that it may be useful as empiric monotherapy for cSSSI and in combination with other antimicrobials in lower respiratory tract infections for which Phase 3 clinical trials are currently exploring. Although not shown in vitro, ceftobiprole may induce resistance due to its broad spectrum of activity. Approval is expected for the treatment of cSSSI.
Practice Change in Community Pharmacy: Quantification of Facilitators (June)
Roberts, A. S, Benrimoj, S. I, Chen, T. F, Williams, K. A, Aslani, P. Tue, 13 May 2008 00:00:00 -0000
BACKGROUND: There has been an increasing international trend toward the delivery of cognitive pharmaceutical services (CPS) in community pharmacy. CPS have been developed and disseminated individually, without a framework underpinning their implementation and with limited knowledge of factors that might assist practice change. The implementation process is complex, involving a range of internal and external factors. OBJECTIVE: To quantify facilitators of practice change in Australian community pharmacies. METHODS: We employed a literature review and qualitative study to facilitate the design of a 43-item "facilitators of practice change" scale as part of a quantitative survey instrument, using a framework of organizational theory. The questionnaire was pilot-tested (n = 100), then mailed to a random sample of 2000 community pharmacies, with a copy each for the pharmacy owner, employed pharmacist, and pharmacy assistant. The construct validity and reliability of the scale were established using exploratory factor analysis and Cronbach's , respectively. RESULTS: A total of 735 (37%) pharmacies responded, with 1303 individual questionnaires. Factor analysis of the scale yielded 7 factors, explaining 48.8% of the total variance. The factors were: relationship with physicians (item loading range 0.59-0.85; Cronbach's a 0.90), remuneration (0.52-0.74; 0.82), pharmacy layout (0.52-0.79; 0.81), patient expectation (0.52-0.85; 0.82), manpower/staff (0.49-0.66; 0.80), communication and teamwork (0.37-0.65; 0.77), and external support/assistance (0.47-0.69; 0.74). CONCLUSIONS: All of the factors demonstrated good reliability and construct validity and explained approximately half of the variance. Implementing CPS requires support not only with the clinical aspects of service delivery, but also for the process of implementation itself, and remuneration models must reflect this. The identified facilitators should be used in a multilevel strategy to integrate professional services into the community pharmacy business, engaging pharmacists and their staff, policy makers, educators, and researchers. Further research is required to determine additional factors impacting the capacity of community pharmacies to implement change.
Correction: Intravenous Human Plasma-Derived Augmentation Therapy in {alpha}1-Antitrypsin Deficiency: From Pharmacokinetic Analysis to Individualizing Therapy (June)
Tue, 13 May 2008 00:00:00 -0000
Formulary Management of Recombinant Factor VIIa at an Academic Medical Center (June)
Owen, P. S, Golightly, L. K, MacLaren, R., Ferretti, K. A, Badesch, D. B Tue, 13 May 2008 00:00:00 -0000
BACKGROUND: Recombinant human coagulation factor VIIa (rVIIa) is a procoagulant indicated for treatment of bleeding in patients with hemophilia. A large proportion of rVIIa utilization is for off-label administration in nonhemophiliac patients with acute hemorrhage. Concerns of potentially inappropriate use, safety, and cost of rVIIa led to efforts to standardize use of this agent. OBJECTIVE: To comparatively describe the utilization of rVIIa upon implementation of an evidence-based guideline at a university hospital. METHODS: With advisory direction from a multidisciplinary task force, an evidence-based guideline for use of rVIIa was developed, approved, and fully implemented. Assessment of appropriateness of use and retrospective review were required for all cases. Effects of these actions were evaluated by auditing and comparing rVIIa use in patients treated in two 6-month observation periods before and after guideline implementation. Outcomes assessed were proportions of patients deemed appropriate to receive rVIIa, compliance with dosing recommendations, and acquisition costs. RESULTS: Twenty-two and 29 patients were treated in the periods before and after guideline implementation, respectively. Patient characteristics were similar, except more cardiothoracic surgeries were performed in patients treated before implementation of the guideline. Indications for rVIIa use were judged appropriate in 21 (95.5%) before-cases and in all (100%) after-cases. The dose was compliant in 1 (4.6%) before-case and 27 (93.1%) after-cases (p < 0.001). Mean dosages of rVIIa administered were 81.8 µg/kg and 45.3 µg/kg in before- and after-cases, respectively (p < 0.001). During the respective periods of observation, amounts of rVIIa purchased monthly averaged 42.6 mg and 21.8 mg, a 49% difference. Semiannual expenditures for rVIIa decreased approximately $110,000 following guideline implementation. Patient outcomes were similar. CONCLUSIONS: A guideline based on currently available evidence can serve to sustain the clinical appropriateness of rVIIa therapy and substantially decrease costs.
Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand (June)
Wheeler, A. J Tue, 13 May 2008 00:00:00 -0000
OBJECTIVE: To describe the treatment pathway and patterns of clozapine use in patients with schizophrenia, including coprescribed psychotropic medications, and compare the extent of coprescribing of clozapine with that of non-clozapine schizophrenia treatment in community mental health services in the Auckland and Northland regions of New Zealand. METHODS: A retrospective chart review was conducted for adult outpatients receiving care from community mental health services on October 31, 2004. Data collected for all patients prescribed an antipsychotic included demographics (sex, age, ethnicity); principal diagnosis (Diagnostic and Statistical Manual of Mental Disorders, 4th edition); comorbid conditions; duration of mental illness; psychiatric admissions; and treatment information (psychotropic medications, with dose and route of administration). If clozapine had been started after the introduction of full government prescription subsidy (February 1999), additional data, including year of initiation and prior antipsychotic history, were collected. Analysis included all outpatients with a diagnosis of schizophrenia (including schizoaffective disorder). RESULTS: Antipsychotics were prescribed for 2796 schizophrenia patients; 32.8% were prescribed clozapine, with a mean dose of 372 mg/day and an average duration of illness of 9.7 years before starting clozapine. Patients who had started treatment after clozapine was funded by the government (59.3%) had received a median of 3 antipsychotic drugs prior to starting clozapine; most of the treatment regimens included 1 second-generation antipsychotic (91.2%). Clozapine patients were less likely to be coprescribed another antipsychotic compared with non-clozapine patients (11.7% vs 17.6%; p < 0.001). Both the clozapine and nonclozapine groups had a low total number of psychotropic medications prescribed (median 2); for clozapine patients, the second drug was most likely to be for treatment of hypersalivation. CONCLUSIONS: Outpatients with treatment-resistant schizophrenia were prescribed clozapine at expected rates; however, treatment was delayed longer than recommended. There is some evidence that access to clozapine for treatment-resistant schizophrenia has improved, possibly as the result of the introduction of government subsidy, guideline dissemination, or increasing experience of clinicians with use of clozapine. In this real-world environment, the number of concomitant psychotropic medications for outpatients with schizophrenia was found to be low; when used concomitantly used with clozapine, they were most commonly used to manage adverse effects.
Clinical Pharmacology & Therapeutics
In This Issue
In This Issue Clinical Pharmacology & Therapeutics 83, 373 (March 2008). doi:10.1038/sj.clpt.6100521
Pharmacoecology: A New Name for an Old Science
C Flexner Pharmacoecology: A New Name for an Old Science Clinical Pharmacology & Therapeutics 83, 375 (March 2008). doi:10.1038/sj.clpt.6100499 Author: C Flexner
News and Views
News and Views Clinical Pharmacology & Therapeutics 83, 380 (March 2008). doi:10.1038/sj.clpt.6100522 Author:
News and Views
News and Views Clinical Pharmacology & Therapeutics 83, 382 (March 2008). doi:10.1038/sj.clpt.6100520
Principles of Clinical Pharmacology, 2nd Edition
SG Carruthers Principles of Clinical Pharmacology, 2nd Edition Clinical Pharmacology & Therapeutics 83, 384 (March 2008). doi:10.1038/sj.clpt.6100485 Author: SG Carruthers
Special Cells, Special Considerations: The Challenges of Bringing Embryonic Stem Cells From the Laboratory to the Clinic
RC AddisJWM BulteJD Gearhart Special Cells, Special Considerations: The Challenges of Bringing Embryonic Stem Cells From the Laboratory to the Clinic Clinical Pharmacology & Therapeutics 83, 386 (March 2008). doi:10.1038/sj.clpt.6100384 Authors: RC Addis, JWM Bulte & JD Gearhart
Sites:
Annual PET Pharmacokinetic Course: Course on application of PET to pharmacokinetics, open to professionals in a wide variety of fields. Held at different locations around the world, next is June 2003 in Montreal, Canada.Cytochrome P450: Identification of a novel transcriptional silencer in the protein-coding region of the human cytochrome P450 2C9 gene.
Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico: Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharmacology and Toxicology., Department of Pharmacology and Toxicology; University of Puerto Rico; Information about the department and the graduate program in Pharm...
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy: Information on research activities in Pharmacology.
Dissolution Solutions Network: Dissolution Solutions Network: Pharmaceutical scientists providing real answers for one another. The latest news, forum, blog and more...
DrugInfo. Searching the Web for Drug Information: A personal Website based on 30-years experience in pharmacology. Provides help to Web browsers in locating the most relevant drug information on the Web.
Elliot Brown Consulting: MedDRA training, products and pharmacovigilance by Dr Elliot Brown Consultancy.Pharmaceutical regulatory affairs, Adverse experiences, adverse events, drug safety surveillance, post marketing surveillance, EMEA, SPMP, MCA ,
FDA Drug Approvals List: Updated weekly as a service by CDER's Division of Data Management and Services.
Institute of Pharmacology University of Bern Switzerland: Information about the institute, its history, research areas and staff.
Institute of Pharmacology, Polish Academy of Sciences: Information about the Institute and its neuropharmacological research, including psychotropic drugs.
Laboratory of Pulmonary Pharmacology: research in human vascular pharmacology, reactivity of bronchial and vascular tissues, role of the eicosanoids and the cholinergic system
New York University Department of Pharmacology: Teaching of medical and graduate students, with research programs in normal growth and differentiation, development and pathology of the nervous system, and mechanisms of normal and abnormal functions of several key hormones.
Novartis Pharma: Here you'll find expert information about diseases, treatments and the full Novartis US product line, and an inside look at where we're headed.
Optimizing a Unimodal Response Function for Binary Variables: Adaptive designs for optimizing a unimodal response function for binary variables.
Ottosen Site for Drug Safety and Pharmacovigilance: Information about drug safety and clinical studies. Includes discussion forum, news and practical information about issues like safety reporting, licensing, contracts, PSUR, E2B, electronic submission.
Pharmacology and Legal Drugs - About.com: Search the power of About's network of topics
Pharmacology-Info.com: Information about pharmacology, toxicology, getting a new drug to market, and FDA approval.
SMR's Case Histories of Drug Discovery: Drug symposium organized by Society for Medicines Research, drug discovery of infliximab, zanamivir, olanzapine, alosetron, leflunomide and celecoxib.
Social Audit - the Antidepressant Web: social audit
The Lycaeum: An Entheogenic Database: The Lycaeum features an entheogen information database, drug experience archive with over 700 reports, search engine which spiders several major drug information sites, psychedelic graphics, transcribed books, community, software, audio, hosted sites, and much more.
The Ones That Stain Blue: Dr. Albert Hofmann
The Virtual Clinical Pharmacologist: Development of inpatient and outpatient anticoagulation and clinical pharmacology services. In conjunction with this we offer several multi-media CD rom products to assist the user in the development of these services. On line lectures are available .
TICTAC: The CD-ROM for drug identification of tablets & capsules
Toxicology-Info.com: Information on toxicology, drug interactions, toxicity and adverse reactions. Part of the ALtruis Biomedical Network.
University of Colorado Health Sciences Center - Department of Pharmacology: Department of Pharmacology and Graduate Program in Pharmacology at the University of Colorado Health Sciences Center at Denver and information about our pharmacology graduate program, curriculum, and research activities in the Pharmacology department. Research interests include: bioinformatics, m...
This directory is based on the Open Directory and may have been modified
